333 related articles for article (PubMed ID: 30669747)
1. [Influence of apatinib and VEGFR2-906T>C polymorphism on clinical outcomes of advanced non-small cell lung cancer patients].
Zhao RH; Zhou YN; Li H; Li R; Zhang WJ; Zong H
Zhonghua Yi Xue Za Zhi; 2019 Jan; 99(2):105-110. PubMed ID: 30669747
[No Abstract] [Full Text] [Related]
2. [Influence of polymorphisms of VEGFR2 on clinical outcomes and safety of advanced non-small-cell lung cancer treated by first line Bevacizumab plus chemotherapy regimens].
Fan HJ; Yuan J; Wu JJ; Jia YX; Ma YH; Li XY
Zhonghua Yi Xue Za Zhi; 2019 Jan; 99(2):99-104. PubMed ID: 30669746
[No Abstract] [Full Text] [Related]
3. Influence of VEGFR2 gene polymorphism on the clinical outcomes of apatinib for patients with chemotherapy-refractory extensive-stage SCLC: a real-world retrospective study.
Geng N; Ding CM; Liu ZK; Song S; Hu WX
Int J Clin Oncol; 2021 Apr; 26(4):670-683. PubMed ID: 33392882
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis.
Liu JY; Zhu BR; Wang YD; Sun X
Int J Clin Oncol; 2020 Jun; 25(6):1195-1205. PubMed ID: 32215805
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes and safety of apatinib monotherapy in the treatment of patients with advanced epithelial ovarian carcinoma who progressed after standard regimens and the analysis of the
Yan Z; Gu YY; Hu XD; Zhao Q; Kang HL; Wang M; Duan W; Guan Y
Oncol Lett; 2020 Sep; 20(3):3035-3045. PubMed ID: 32782621
[TBL] [Abstract][Full Text] [Related]
6. The Influence of KDR Genetic Variation on the Efficacy and Safety of Patients With Advanced NSCLC Receiving First-Line Bevacizumab Plus Chemotherapy Regimen.
Geng N; Su J; Liu Z; Ding C; Xie S; Hu W
Technol Cancer Res Treat; 2021; 20():15330338211019433. PubMed ID: 34060368
[TBL] [Abstract][Full Text] [Related]
7. [The impact of genetic variation of KDR on clinical outcomes of advanced colorectal cancer patients treated by first line bevacizumab based regimens].
Wang HX; Mei X; Gong TX; Han N; Liu P; Wang J; Zhang ZM
Zhonghua Yi Xue Za Zhi; 2018 Sep; 98(34):2737-2742. PubMed ID: 30220171
[No Abstract] [Full Text] [Related]
8. Clinical Outcomes and Safety of Apatinib Mesylate in the Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer in Patients Who Progressed After Standard Therapy and Analysis of the
Song ZZ; Zhao LF; Zuo J; Fan ZS; Wang L; Wang YD
Onco Targets Ther; 2020; 13():603-613. PubMed ID: 32021302
[TBL] [Abstract][Full Text] [Related]
9. Implication of
Li X; Cheng Y; Zhu B; Geng M; Yan P; Hu M
Technol Cancer Res Treat; 2022; 21():15330338221080993. PubMed ID: 35443836
[No Abstract] [Full Text] [Related]
10. [Influence of genetic variation of programmed death-ligand 1 (PD-L1) on the prognosis of patients with non-small cell lung cancer who received platinum-based adjuvant chemotherapy].
Zhang GW; Cheng RR; Zhang FR; Li P; Chu HY; Song XJ; Zhang GJ
Zhonghua Yi Xue Za Zhi; 2020 Sep; 100(34):2682-2688. PubMed ID: 32921017
[No Abstract] [Full Text] [Related]
11. Influence of KDR Genetic Variation on the Efficacy and Safety of Patients with Chemotherapy Refractory Metastatic CRC Who Received Apatinib Treatment.
Bai M; Li ZG; Ba Y
Int J Gen Med; 2021; 14():1041-1055. PubMed ID: 33790633
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: Apatinib treatment in nonsquamous NSCLC.
Wu D; Liang L; Nie L; Nie J; Dai L; Hu W; Zhang J; Chen X; Han J; Ma X; Tian G; Han S; Long J; Wang Y; Zhang Z; Xin T; Fang J
Asia Pac J Clin Oncol; 2018 Dec; 14(6):446-452. PubMed ID: 29573236
[TBL] [Abstract][Full Text] [Related]
13. Association Between
Hu W; Li B; Geng N; He X; Ge H; Wang P; Ding C
Int J Gen Med; 2021; 14():2703-2714. PubMed ID: 34188525
[TBL] [Abstract][Full Text] [Related]
14. [The influence of Thymidine Phosphorylase genetic variation on clinical outcomes and safety of colorectal cancer patients received adjuvant chemotherapy after R0 resection].
Du YB; Zhang TF; Cui K; Jin SL; Xi Y; Ma W
Zhonghua Yi Xue Za Zhi; 2018 Aug; 98(32):2569-2573. PubMed ID: 30220141
[No Abstract] [Full Text] [Related]
15. [Efficacy and Survival Analysis of Apatinib in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer after Failure of First-line Treatment].
Wang X; Zhang W; Du W; Zhang X; Ren X; Cao S
Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):761-768. PubMed ID: 29167006
[TBL] [Abstract][Full Text] [Related]
16. [Clinical study of apatinib combined with chemotherapy for advanced non-small cell lung cancer with negative driving genes].
Li YF; Jiang HY; Li Q; Zhu M; Lyu J; Zhao HY
Zhonghua Zhong Liu Za Zhi; 2019 Oct; 41(10):775-781. PubMed ID: 31648501
[No Abstract] [Full Text] [Related]
17. [Clinical outcomes of gastric cancer patients received capecitabine based adjuvant chemotherapy and the corresponding pharmacogenomics analysis].
Chen WC; Wu G; Zhang W; Zhu YZ; Zhou Y; Zhang H; Xia XB; Sun PC
Zhonghua Yi Xue Za Zhi; 2018 Nov; 98(42):3420-3425. PubMed ID: 30440137
[No Abstract] [Full Text] [Related]
18. The influence of PD-L1 genetic variation on the prognosis of R0 resection colorectal cancer patients received capecitabine-based adjuvant chemotherapy: a long-term follow-up, real-world retrospective study.
Su J; Dai B; Yuan W; Wang G; Zhang Z; Li Z; Liu J; Song J
Cancer Chemother Pharmacol; 2020 May; 85(5):969-978. PubMed ID: 32314029
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms in epidermal growth factor receptor (EGFR) and AKT1 as possible predictors of clinical outcome in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.
Zhang X; Fan J; Li Y; Lin S; Shu P; Ni J; Qin S; Zhang Z
Tumour Biol; 2016 Jan; 37(1):1061-9. PubMed ID: 26269114
[TBL] [Abstract][Full Text] [Related]
20. Association of T2285C polymorphism in PARP1 gene coding region with its expression, activity and NSCLC risk along with prognosis.
Wang Y; Xia XB; Tang HZ; Cai JR; Shi XK; Ji HX; Yan XN; Xu T
Mutagenesis; 2021 Aug; 36(4):281-293. PubMed ID: 34132814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]